SAB Biotherapeutics, Inc. (SABS) Dividend History

Company News

• SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates

  SAB BIO, a clinical-stage biopharmaceutical company, reported financial results for Q1 2025. The company made progress on its type 1 diabetes program, including positive Phase 1 data for its lead candidate SAB-142. SAB BIO also achieved manufacturing milestones and saw a decrease in R&D and G&A expenses.

  GlobeNewswire Inc.
• SAB BIO to Participate in Upcoming Investor Conferences

  SAB BIO, a clinical-stage biopharmaceutical company, announced its participation in upcoming investor conferences to discuss its lead asset, SAB-142, which targets type 1 diabetes with a disease-modifying approach.

  GlobeNewswire Inc.
• SAb Biotherapeutics Rebrands as SAB BIO

  New name, logo and website updates, stock symbol will remain SABS

  GlobeNewswire Inc.
• SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

  MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB’s Senior Program Manager, Eric Sandhurst, Ph.D, and published online in the journal Diabetes®.

  GlobeNewswire Inc.
• FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

  FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

  GlobeNewswire Inc.